Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

NCT00654927 is registered in ClinicalTrials.gov with Acorda Therapeutics as lead sponsor.

NCT NCT00654927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00654927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis
Lead sponsor
Acorda Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2003
Completion date
April 30, 2011
Enrollment
177 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis